|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
45,530,000 |
Market
Cap: |
21.00(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2666 - $1.13 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Passage Bio is a genetic medicines company focused on developing therapies for monogenic central nervous system disorders. Co. is developing PBGM01, which utilizes a proprietary AAVhu68 capsid for the treatment of GM1 gangliosidosis. Co. is also developing PBFT02, which utilizes an AAV1 capsid for the treatment of frontotemporal dementia-progranulin deficiency. Co. is also developing PBKR03, which utilizes a proprietary AAVhu68 capsid for the treatment of Krabbe disease. Co. has various programs in the research stage under its license agreement with the Trustees of the University of Pennsylvania including: PBML04 for metachromatic leukodystrophy and PBAL05 for amyotrophic lateral sclerosis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
829,998 |
829,998 |
Total Buy Value |
$0 |
$0 |
$525,557 |
$525,557 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
4 |
4 |
Total Shares Sold |
968,283 |
1,341,709 |
1,970,840 |
2,027,699 |
Total Sell Value |
$325,675 |
$572,890 |
$1,015,039 |
$1,066,625 |
Total People Sold |
1 |
2 |
2 |
5 |
Total Sell Transactions |
9 |
16 |
26 |
32 |
End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-06-26 |
4 |
S |
$0.33 |
$70,375 |
I/I |
(213,257) |
6,066,343 |
|
-23% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-06-25 |
4 |
S |
$0.33 |
$45,804 |
I/I |
(138,800) |
6,279,600 |
|
-25% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-06-24 |
4 |
S |
$0.35 |
$81,060 |
I/I |
(231,600) |
6,418,400 |
|
-16% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-04-24 |
4 |
S |
$0.32 |
$21,822 |
I/I |
(68,195) |
6,650,000 |
|
-25% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-04-23 |
4 |
S |
$0.34 |
$30,372 |
I/I |
(89,328) |
6,718,195 |
|
-21% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-04-22 |
4 |
S |
$0.34 |
$26,537 |
I/I |
(78,049) |
6,807,523 |
|
-16% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-04-17 |
4 |
S |
$0.33 |
$25,440 |
I/I |
(77,090) |
6,885,572 |
|
-23% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-04-16 |
4 |
S |
$0.33 |
$20,341 |
I/I |
(61,638) |
6,962,662 |
|
-24% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-04-15 |
4 |
S |
$0.38 |
$3,924 |
I/I |
(10,326) |
7,024,300 |
|
-10% |
|
Borthwick Kathleen |
CFO |
|
2025-02-11 |
4 |
S |
$0.53 |
$1,686 |
D/D |
(3,183) |
41,283 |
|
37% |
|
Borthwick Kathleen |
CFO |
|
2025-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
44,466 |
|
- |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-01-14 |
4 |
S |
$0.60 |
$47,414 |
I/I |
(79,024) |
7,034,626 |
|
38% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-01-13 |
4 |
S |
$0.64 |
$11,511 |
I/I |
(17,986) |
7,113,650 |
|
45% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-01-10 |
4 |
S |
$0.66 |
$83,298 |
I/I |
(126,209) |
7,131,636 |
|
55% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-01-08 |
4 |
S |
$0.68 |
$51,005 |
I/I |
(75,007) |
7,257,845 |
|
52% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-01-07 |
4 |
S |
$0.71 |
$37,301 |
I/I |
(52,536) |
7,332,852 |
|
57% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2025-01-06 |
4 |
S |
$0.77 |
$15,000 |
I/I |
(19,481) |
7,385,388 |
|
60% |
|
Nichols Weston |
10% Owner |
|
2024-12-27 |
4 |
B |
$0.65 |
$241,038 |
I/I |
373,645 |
9,256,953 |
1.5 |
-50% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2024-12-20 |
4 |
S |
$0.60 |
$138,193 |
I/I |
(230,321) |
7,404,869 |
|
46% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2024-12-11 |
4 |
S |
$0.80 |
$64 |
I/I |
(80) |
7,635,190 |
|
57% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2024-12-10 |
4 |
S |
$0.80 |
$6,412 |
I/I |
(8,015) |
7,635,270 |
|
58% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2024-12-09 |
4 |
S |
$0.84 |
$45,512 |
I/I |
(54,181) |
7,643,285 |
|
56% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2024-12-06 |
4 |
S |
$0.82 |
$17,140 |
I/I |
(20,903) |
7,697,466 |
|
54% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2024-12-04 |
4 |
S |
$0.79 |
$60,198 |
I/I |
(76,200) |
7,718,369 |
|
56% |
|
Nichols Weston |
10% Owner |
|
2024-11-27 |
4 |
B |
$0.67 |
$19,663 |
I/I |
29,300 |
8,883,308 |
1.5 |
-46% |
|
93 Records found
|
|
Page 1 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|